Faecal Microbiota Transplantation After Allogeneic Stem Cell Transplantation

The aim of this study is to assess the Fecal Microbiota Transplantation (FMT) efficacy in the prevention of allogeneic hematopoietic stem cell transplantation (allo-HSCT) complications and particularly Graft versus Host Disease (GvHD). The hypothesis of this study is that allogeneic FMT may improve outcomes of these patients.

Trial Details

NCT ID

NCT04935684

Phase

PHASE2

Sponsor

University Hospital, Clermont-Ferrand

Status

RECRUITING

Cancer Type

Lymphoma

Interventions

Fecal Microbiota Transplantation

Locations (sample)

Amiens, France|49.9,2.3
Angers, France|47.47156,-0.55202
Besançon, France|47.24878,6.01815
Clermont-Ferrand, France|45.77969,3.08682
Clermont-Ferrand, France|45.77969,3.08682

Key Eligibility Criteria

Patient aged 18 or over
Men and women
Patients affiliated with a social-security organization
Patients undergoing a myelo-ablative allo-HSCT for a controlled haematologic malignant disease, with peripheral stem cells, whatever the type of do…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →